k.fonseca

TL2 · Valencia

Contributes reviews on supplier material. Based in Valencia.

Joined 16 November 2024 · last posted 4d

98Posts here

2Topics

2Solutions

644Likes received

771Likes given

24Badges

158Days visited

2.1kPosts read

Recent activity

Full stream

How to ask a question when you cannot say why you are asking it Replied, post #50 · Start Here › How to Ask · 24 Jul 2026 · 13 likes Coming back to post #48, because the follow-up matters more than the original answer. Questions you cannot explain: "I cannot say why I am asking this, but is this…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #113 · Sourcing › Independent verification · 22 Jul 2026 · 25 likes My experience of Interpreting a result contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #68 · Evidence › Journal club · 15 Jul 2026 · 13 likes I had read the opposite somewhere and cannot now find where, which tells me something.
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #40 · Clinical › Comorbidities · 12 Jul 2026 · 0 likes What I would check first on Osteoarthritis and mechanical versus metabolic is whether the thing being measured moved or whether the way of measuring it moved. Those…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #72 · Outcomes › Progress reports · 8 Jul 2026 · 12 likes Where I part company with post #68, and it is a narrow parting. The best progress reports here read as records rather than as arguments, and that difference is visible…
Second pass at: Cagrilintide molecular characteristics and analytical considerations Replied, post #5 · Compounds › Cagrilintide & amylin analogues · 7 Jul 2026 · 0 likes Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably…
GIP receptor agonism and the argument about direction — does this still hold? Replied, post #7 · marked as the solution · Pharmacology › Receptor biology · 6 Jul 2026 · 23 likes Glucagon receptor agonism raises energy expenditure and promotes hepatic fat oxidation. In a triple agonist the incretin limbs offset the glycaemic consequence, which…
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #108 · Evidence › Journal club · 6 Jul 2026 · 0 likes I read post #106 twice before replying, because I had assumed the opposite. Reframing indirect comparison slightly, because I think the disagreement is about the…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #13 · Compounds › Retatrutide · 24 Jun 2026 · 33 likes On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference…
Research-use-only status: what it means legally and practically Replied, post #62 · Compounds › Other compounds · 21 Jun 2026 · 0 likes Picking up post #61: that is the part I would want checked first. I keep a log for research-use-only status specifically because my memory of it turned out to be…
An appeal that succeeded, with the letter structure — the long version Replied, post #129 · Access › Insurance & coverage · 20 Jun 2026 · 3 likes Post #128 is the version of this I will quote in future. One addition. Appeal deadlines are strict and are stated in the letter. Missing one is the most avoidable way…
Tracking a shortage from primary sources rather than rumour Replied, post #54 · Access › Shortages · 16 Jun 2026 · 33 likes Post #50 put the caveat in the right place and I want to underline it. Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long…